Halozyme Therapeutics Inc
(NAS:HALO)
$
48.13
0.1 (0.21%)
Market Cap: 6.12 Bil
Enterprise Value: 6.95 Bil
PE Ratio: 15.94
PB Ratio: 13.52
GF Score: 87/100 Halozyme Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021 / 03:20PM GMT
Release Date Price:
$39.46
(-1.99%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Well, good morning, everyone, and welcome to the 11:20 a.m. session of 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover both European and U.S. biopharma names here at the firm. It's my great pleasure to be hosting Halozyme Therapeutics today in a fireside chat. And with that, let me welcome company President -- company CEO, Helen Torley. Helen, it's great to see you again and welcome.
Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director
Thanks so much, Graig. Really looking forward to today.
Questions & Answers
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Sure. Halozyme is a very unique company and a unique story, I think. It's a company we've been positive on for some time. But for those who may be new to the story or perhaps revisiting
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot